← Therapy pipeline
Investigational · Obesity development

Enicepatide

CT-388 · RO7795068 · Roche

Once-weekly GLP-1/GIP dual agonist in Phase 3 weight-management trials.

GLP-1GIP
Other study areas
Type 2 diabetes
Selected program areas, not approvals. See the full profile for individual trials.
Obesity stagePhase 3Updated as of November 2026
SponsorRoche
TargetsGLP-1 + GIP
RouteInjection
DevelopmentObesity-specific
01 / Evidence

Selected study results

CT-388-103Placebo-adjusted weight-loss differencePlacebo-adjusted weight-loss difference: −22.5 percentage points · 48 weeks · Phase 2
Phase 2 · Injection · Sponsor-reported numerical results

Placebo-adjusted weight-loss difference · 48 weeks

Study focus: Weight management without type 2 diabetes

Placebo-adjusted difference, not the total change in the active arm.

Placebo-adjusted difference. Treatment-regimen difference was 18.3 percentage points.

Difference versus placebo
22.5 percentage points

Adults with obesity/overweight and a complication, without type 2 diabetes · 24 mg weekly after escalation · Trial N=469 · Efficacy estimand; sponsor topline. Results & methods ↗

CT-388-104Mean body-weight reductionBody weight decreased 15.5% · 48 weeks · Phase 2
Phase 2 · Injection · Sponsor-reported numerical results

Mean body-weight reduction · 48 weeks

Study focus: Weight management with type 2 diabetes

Investigational regimen
15.5%

Adults with type 2 diabetes and obesity/overweight · Enicepatide 24 mg weekly · Trial N=447 · Sponsor topline; placebo weight result and estimand not given. Results & methods ↗

Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.

02 / How it works

Mechanism at a glance

GLP-1GLP-1Targeted
GIPGIPTargeted
GCGglucagon—
AMYamylin—
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

InjectionOnce weekly
Phase 3Initiated
Milestone → next

Latest: ENITH-1/2 Phase 3 weight-management trials ongoing; Phase 2 T2D/obesity topline released September 22.

Next: Full Phase 2 results and subsequent development updates; the CT-388-104 registry is completed.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 3 studies2 records

Phase 2 studies2 records

Phase 2

CT-388-103

Weight management
Study: CompletedResults: Sponsor results shown aboveStatus reviewed November 2026

48-week study in adults with obesity or overweight and at least one weight-related comorbidity; without type 2 diabetes. Published/sponsor results are shown in the evidence section.

Phase 2

CT-388-104

Weight management with type 2 diabetes
Study: CompletedResults: Sponsor results shown aboveStatus reviewed November 2026

48-week study in adults with obesity or overweight and type 2 diabetes; separate from CT-388-103.